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Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and platelet count (PC) were 
shown to be prognostic in several solid malignancies. We analysed 603 R0 resected patients to assess 
whether NLR, PLR and PC correlate with other well-known prognostic factors and survival of patients 
with colorectal cancer (CRC). Receiver operating characteristic (ROC) curve analysis was performed to 
define cut-off values for high and low ratios of these indices. Univariate and multivariate analysis were 
used to determine the prognostic value of NLR, PLR and PC for overall and cancer-related survival. 
The distribution of NLR, PLR and PC in CRC patients was compared with 5270 healthy blood donors. 
The distribution of NLR, PLR and PC was significantly different between CRC patients and controls (all 
p < 0.05). A significant but heterogeneous association was found between the main CRC prognostic 
factors and high values of NLR, PLR and PC. Survival appeared to be worse in patients with high NLR 
with cancers in AJCC/UICC TNM Stages I-IV; nonetheless its prognostic value was not confirmed for 
cancer-related survival in multivariate analysis. After stratification of patients according to AJCC/UICC 
TNM stages, high PC value was significantly correlated with overall and cancer-related survival in TNM 
stage IV patients.
Despite substantial improvement in early diagnosis, surgical techniques and adjuvant therapies, colorectal cancer 
(CRC) remains the third most commonly diagnosed cancer and the third leading cause of cancer-related mor-
tality worldwide1.
The most appropriate management of CRC entails a deep knowledge of the pivotal role played by molecular 
factors involved in the pathogenesis of this condition. Such knowledge can also help identifying prognostic bio-
markers that can predicting the outcome. The prognostic value of many putative biomarkers has been investigated 
so far2–4.
Amongst these, peripheral blood neutrophil-to lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), 
as well as platelet count (PC) have recently emerged as potentially useful tests, since their value may mirror a shift 
of the immune response in patients with colorectal malignancies.
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Inflammation plays a crucial role in the pathogenesis and progression of many types of cancer. Some recent 
studies demonstrated that systemic inflammatory response correlates with postoperative survival in different 
cancer patients5, 6.
Moreover, systemic inflammatory response to tumours is associated with abnormalities of several blood com-
ponents, especially neutrophils and lymphocytes. Several hypotheses have been proposed to explain the relation-
ship between cancer and increased values of both PC and plasma fibrinogen7, 8. More specifically, platelets release 
angiogenic and putative tumour growth factors such as platelet factor 4 (PF4), transforming growth factor beta 
(TGF-β) and platelet-derived growth factor (PDGF), all of which promote cancer progression and endotelial cell 
growth9–11.
The aim of this retrospective study was to evaluate the prognostic value of preoperative neutrophils to lym-
phocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and PC in patients undergoing potentially curative (R0) 
resection for colorectal cancer.
Results
Distribution of NLR, PLR and PC in study group and controls. Overall, 603 out of the 1075 patients 
with CRC observed were finally included in our study according to our inclusion criteria. The distribution of 
NLR, PLR and PC in cases and controls are shown in Fig. 1. The mean (±SD) preoperative values of the CRC 
patients were significantly higher than those of the control population (NLR 3.1 ± 1.8 vs. 1.8 ± 1; p < 0.001, PLR 
194 ± 98 vs. 126 ± 38; p < 0.001; PC 298 ± 104 × 109/L vs. 241 ± 51 × 109/L; p < 0.001) (Table 1). The following 
Figure 1. Distribution of (a) NLR, (b) PLR, and (c) PC stratified by study and control groups.
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optimal cut-off values were identified: 3.5 for NLR (i.e. low [L]-NLR ≤ 3.5 and high [H]-NLR > 3.5), 350 for PLR 
(i.e. low [L]-PLR ≤ 350 and high [H]-PLR > 350) and 350 × 109/L for PC (i.e. low [L]-PC ≤ 350 × 109/L and high 
[H]-PC > 350 × 109/L), respectively (see Supplementary Fig. S1). According to these thresholds, increased values 
were observed in 26.2% of CRC cases versus 3.2% of the controls for NLR, 6.8% of cases versus 0.0004% of con-
trols for PLR, and 24.9% of cases versus 2.7% of controls for PC (all p < 0.001).
Correlation between NLR, PLR and PC and clinicopathological variables. The correlations of 
NLR, PLR and PC with clinicopathological variables are shown in Table 2. H-NLR was more frequently observed 
in patients with increased age (p = 0.026), advanced pT (p < 0.001), TNM stage tumours (p < 0.001), metastatic 
disease (p < 0.001) and CEA positive cancers (p = 0.017). H-PLR was observed more frequently in advanced pT 
Patients Controls p value
Mean (±SD) age (years) 68.2 (±12.9) 41.2 (±12) <0.001
Male gender 347 (57.5%) 3946 (74.8%) <0.001
Mean (±SD) neutrophil count 4.7 (±1.8) 3.6 (±2.9) <0.001
Mean (±SD) lymphocyte count 1.7 (±0.7) 2 (±0.6) <0.001
Mean (±SD) PC 298 (±104) 240 (±51) <0.001
Mean (±SD) NLR 3.1 (±1.8) 1.8 (±1) <0.001
Mean (±SD) PLR 194 (±98) 126 (±38) <0.001
Table 1. NLR, PLR and PC of the 603 patients under study and of the 5270 blood donors cases of the control 
group.
No. of patients H-NLR H-PLR H-PC
Age p = 0.026 p = 0.747 p = 0.398
 ≤68.9 years 299 66 (22.1%) 19 (6.4%) 79 (26.4%)
 >68.9 years 304 92 (30.3%) 22 (7.2%) 71 (23.4%)
Gender p = 0.263 p = 0.417 p = 0.013
 Male 347 97 (28%) 21 (6.1%) 73 (21%)
 Female 256 61 (23.8%) 20 (7.8%) 77 (30.1%)
 Tumour location p = 1.000 p = 0.280 p = 0.006
 Colon 438 115 (26.3%) 33 (7.5%) 122 (27.9%)
 Rectum 165 43 (26.1%) 8 (4.8%) 28 (17%)
Depth of invasion (pT) p < 0.001 p = 0.023 p < 0.001
 pT1 77 7 (9.1%) 0% 8 (10.4%)
 pT2 76 22 (28.9%) 5 (6.6%) 12 (15.8%)
 pT3 270 63 (23.3%) 16 (5.9%) 70 (25.9%)
 pT4a 122 42 (34.4%) 13 (10.7%) 37 (30.3%)
 pT4b 58 24 (41.4%) 7 (12.1%) 23 (39.7%)
Node involvement (pN) p = 0.679 p = 0.374 p = 0.172
 pN0 380 95 (25%) 26 (6.9%) 88 (23.2%)
 pN1 155 44 (28.4%) 8 (5.2%) 39 (25.2%)
 pN2 68 19 (27.9%) 7 (10.3%) 23 (33.8%)
Systemic metastasis (M) p < 0.001 p = 0.059 p = 0.101
 M0 563 137 (24.3%) 36 (6.4%) 136 (24.2%)
 M1a 33 15 (45.5%) 3 (9.1%) 10 (30.3%)
 M1b 7 6 (85.7%) 2 (28.1%) 4 (57.1%)
AJCC/UICC TNM Stage p < 0.001 p = 0.106 p = 0.008
 Stage I 130 27 (20.8%) 5 (3.8%) 18 (13.8%)
 Stage II 237 64 (27%) 21 (8.9%) 65 (27.4%)
 Stage III 196 46 (23.5%) 10 (5.1%) 53 (27%)
 Stage IV 40 21 (52.5%) 5 (12.5%) 14 (35%)
CEA serum levelb p = 0.017 p = 0.818 p = 0.005
 ≤5 ng/mL 303 75 (24.8%) 21 (6.9%) 69 (22.8%)
 >5 ng/mL 92 35 (38%) 7 (7.6%) 35 (38%)
Table 2. Correlations between NLR, PLR and PC and main clinicopathological variables for the 603 patients 
under study.
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stage tumours (p = 0.023), although the percentage of patients with H-PLR did not exceeded 12%. H-PC was 
observed more frequently in the female gender (p = 0.013), colon tumour location (p = 0.006), advanced pT 
(p < 0.001), TNM stage tumours (p = 0.008) and CEA positive cancer (p = 0.005).
No differences in NLR and PLR were observed according to tumour grading, lymphatic, vascular and per-
ineural invasion. Conversely, H-PC was found to be significantly associated with poor cancer differentiation 
(G3 tumours: 23.3% vs. 8.8%; p < 0.001), vascular invasion (VI + tumours: 32.2% vs. 20.7%; p = 0.013), peri-
neural invasion (NI + tumours: 32.5% vs. 23.3%; p = 0.041) and mucinous histotype (mucinous tumours: 34.5% 
vs. 22.9%; p = 0.046). No difference in PC values was observed in relation to lymphatic invasion (p = 0.834) and 
inflammatory reaction (p = 0.986).
NLR, PLR and PC and survival analysis. Overall and cancer-related survival rates in relationship to the 




Age p < 0.001 p = 0.022
 ≤68.9 years 299 85.9 89.4
 >68.9 years 304 64.6 79.3
Gender p = 0.055 p = 0.052
 Male 347 73.7 82.6
 Female 256 77.2 87.7
Tumour location p = 0.699 p = 0.818
 Colon 438 74.8 84.1
 Rectum 165 76.1 86.4
Depth of invasion (pT) p < 0.001 p < 0.001
 pT1 77 89.9 100
 pT2 76 86.5 90.9
 pT3 270 80.8 90.8
 pT4a 122 54.5 65.2
 pT4b 58 55.2 61.5
Node involvement (pN) p < 0.001 p < 0.001
 pN0 380 81.6 92.5
 pN1 155 71.1 78.6
 pN2 68 44.7 46.9
Systemic metastasis (M) p < 0.001 p < 0.001
 M0 563 77.8 87.8
 M1a 33 46.5 50.8
 M1b 7 0 0
AJCC/UICC TNM Stage p < 0.001 p < 0.001
 Stage I 130 89.2 97
 Stage II 237 79.1 91.6
 Stage III 196 68 75.5
 Stage IV 40 37.9 45.8
CEA serum levela p < 0.001 p < 0.001
 ≤5 ng/mL 303 78.6 86.1
 >5 ng/mL 92 58.3 73.2
Neutrophil-to-lymphocyte ratio p < 0.001 p = 0.022
 L-NLR 445 79.8 86.6
 H-NLR 158 62.5 79.4
Platelet-to-lymphocyte ratio p = 0.070 p = 0.239
 L-PLR 562 75.9 86.6
 H-PLR 41 65.9 79.4
Platelet count p = 0.122 p = 0.151
 L-PC 453 76.3 85.2
 H-PC 150 71.8 83.5
Table 3. Five-year overall and cancer-related survival rates according to the main clinicopathological 
characteristics, NLR, PLR and PC for the 603 patients under study. aCEA serum level was available for 401 
patients.
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Age, depth of tumour invasion (pT), node involvement (pN), metastatic disease (M), TNM stage and CEA 
positivity were confirmed to be significant predictors of overall and cancer-related survival. Patients with H-NLR 
had lower 5-year overall survival (p < 0.001) and worse cancer-related survival rate (p = 0.020) (Fig. 2). No dif-
ferences in overall and cancer-related survival were observed between high and low values of both PLR and PC 
(Table 3) (see Supplementary Figs S2 and S3).
In the Cox regression model, H-NLR, H-PLR and H-PC were found to be independent predictors of 5-year 
overall survival but not cancer-related survival after multiple adjustments (Table 4) (see Supplementary Tables S1 
and S2).
To further investigate the prognostic role of NLR, PLR and PC, the survival rates were stratified according to 
AJCC/UICC TNM stages. No differences in 5-year overall and cancer-related survival were observed between 
high and low values of both NLR and PLR across TNM stages I to IV (all p > 0.05). Similarly, no differences 
in 5-year overall and cancer-related survival were observed between high and low values of PC among TNM 
stages I to III (all p > 0.05). Notably, H-PC was found to be a negative predictor of overall and cancer-related 
survival compared to L-PC in patients with AJCC/UICC TNM stage IV tumours (overall survival, p = 0.002; 
cancer-related survival, p = 0.041) (Fig. 3).
Discussion
Increased values of both NLR and PLR were recently found to be negative predictors of survival in several malig-
nancies such as oesophageal, hepato-bilio-pancreatic prostate cancer12–16 as well as CRC6, 17, 18.
The main findings of this study are: (1) the distribution of NLR, PLR and PC was found to be significantly 
different between CRC patients and controls; (2) a significant but variable association was found between the 
main known CRC prognostic factors and H-NLR, H-PLR and H-PC; (3) H-NLR was associated with significantly 
poorer overall survival in univariate as well multivariate analysis, but it had no impact on cancer-related survival; 
(4) after stratification of patients according to AJCC/UICC TNM stage, H-PC was significantly related to overall 
and cancer-related survival.
Although the clinical significance of NLR is still unclear, it has been pointed out that this parameter may glob-
ally reflect a shift of the immune response towards a pro-inflammatory pattern (i.e. high value of neutrophils) bal-
anced by a depression of cell-mediated immunity (i.e. low value of lymphocytes). Since platelets are active players 
in inflammatory response, both thrombocytosis and high PLR are probably part of the same pathophysiology 
process13. Cancer cells produce many pro-inflammatory cytokines and chemokines such as GCSF, IL-1 and IL-6, 
Figure 2. Kaplan-Meier curves for (a) overall survival (p < 0.001) and (b) cancer-related survival (p = 0.022) 
stratified by NLR.
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but they are also actively involved in cytotoxic T-cell and natural killer cell suppression19. Altogether these aspects 
may contribute to generate a pro-inflammatory and immunosuppressive milieu20.
Interestingly, Turner et al. recently analysed local chronic inflammatory cell infiltrate together with sys-
temic inflammation (i.e. NLR) in stage II CRC and showed that the combination of the two parameters have an 
Overall Survival Cancer-related Survival
HR (95% CI) p value HR (95% CI) p value
Age (years) <0.001 0.017
 ≤68.9 years — —
 >68.9 years 2.98 (2.07–4.29) 1.69 (1.09–2.61)
Gender 0.10 0.08
 Female — —
 Male 1.33 (0.95–1.87) 1.50 (0.96–2.36)
Histological Type 0.46 0.10
 Adenocarcinoma — —
 Mucinous 0.85 (0.56–1.30) 0.61 (0.33–1.01)
TNM Stage <0.001 <0.001
 Stage I — —
 Stage II 1.59 (0.90–2.82) 2.73 (0.92–8.13)
 Stage III 2.92 (1.66–5.13) 9.65 (3.43–27.14)
 Stage IV 6.49 (3.45–12.21) 29.78 (10.22–86.75)
Neutrophil-to-lymphocyte ratio 0.003 0.40
 L-NLR — —
 H-NLR 1.15 (0.86–1.54) 1.22 (0.77–1.93)
Table 4. Multivariable survival analysis including neutrophil-to-lymphocyte ratio (NLR) for the 603 patients 
under study. aValues in parentheses are 95% confidence intervals. Hazard ratio and p values were derived from 
Cox regression analysis, controlling for all other variables.
Figure 3. Kaplan-Meier curves for (a) overall survival (p = 0.002) and (b) cancer-related survival (p = 0.041) 
stratified by PC in AJCC/UICC TNM Stage IV.
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increased prognostic value, which is also independent from standard clinical and pathological criteria. In this 
experience, cases with high intratumoural inflammation and low systemic inflammation showed a significantly 
better prognosis, whilst cases with low intratumoural inflammation and high systemic inflammatory response 
had a worse one18.
Beside cancer cells, solid tumours are composed of heterogeneous cell populations, including endothelial cells, 
fibroblasts and pericytes. Different cells produce several mediators capable of recruiting different leukocytes pop-
ulations from the circulation to the tumour site. Within solid tumours, the myeloid population is certainly one of 
the most represented. Amongst these cells, tumour associated monocytes (TAM) and immature myeloid-derived 
suppressor cells (MDSC) play several important functions such as immunosuppression, angiogenesis tumour 
growth and cancer dissemination21, 22. It is possible that larger, less differentiated and more advanced tumours, 
(T stage but also N and M stages), bear more effective chemotactic activity towards the myeloid lineage, which 
in turn promotes progression of the cancer. It is reasonable to suggest that each individual immune response 
to cancer cells may contribute to define part of the biological behaviour of a malignancy. In this respect, it is 
also conceivable that a lower intratumoural inflammation and a higher systemic inflammatory response might 
translate in a decreased immunological local control, so engendering a systemic pro-inflammatory environment 
which ultimately facilitates cancer progression. Factors that could drive one or another type of immune response 
remain unknown so far.
The significant difference of NLR, PLR and PC values between CRC patients and healthy controls is one of 
the more interesting findings of our study. The sample size of the control population in our investigation is the 
largest in which NLR and PLR have ever been assessed, and this contributes to reinforce the clinical significance 
of our data.
Although the mean patient age was different between control and study groups, NLR, PLR and PC did not 
change in parallel to the increased age of the patients (Supplementary Figs S4 and S5). The higher frequency of 
H-NLR in patients with an age over the median value is likely due to the higher number of advanced pT and TNM 
stage tumours in this specific group (P < 0.005, data not shown).
Notably, the cut-off values of NLR, PLR and PC that we have calculated (i.e. 3.5, 350 and 350 × 109/L) par-
tially differ from those reported in other investigations. This is not surprising since this difference may be due to 
the analysis of a different study population or to the use of a different haematological analyser, highlighting the 
importance of local calculation of predictive thresholds for these parameters.
In our study, H-NLR, H-PLR and H-PC were found to be significantly associated with some well-known CRC 
prognostic factors. More specifically, H-NLR correlated with pT, TNM stage, presence of metastatic disease and 
CEA positivity. H-PLR was associated with advanced pT tumours, whereas H-PC correlated with female gender 
and colon tumour location. A similar correlation between NLR and tumour burden was previously described. 
More specifically, in a retrospective study including 504 patients with stage II and III colon cancer, Absenger et al. 
found that NLR independently predicted the time to recurrence23.
Another study24 described a significant correlation between H-NLR, size (pT) and metastatic disease burden, 
although the cut-off value was slightly lower than that identified in our investigation (i.e. 3.0 versus 3.5). NLR was 
also found to be an independent predictor of worse outcome within the same stage cancer (stage IIA), proving to 
be an important factor in the evaluation of adjuvant therapy25.
H-PC was an independent predictor factor of both overall and cancer-related survival. Interestingly, H-PC was 
found to be an independent predictor factor of both 5-year overall and cancer-related survival only in patients 
with stage IV tumours.
The prognostic value of PC in CRC has been previously investigated. Although some results were generated 
in retrospective or underpowered studies, thrombocytosis at the time of diagnosis of CRC has been convincingly 
associated with worse disease free and overall survival8. Renal26, gynaecological27 and lung cancers28, 29 have also 
shown to have an elevated PC at the time of diagnosis. Finally, thrombocytosis could identify a patient subgroup 
in whom cytokine activation is driving a more aggressive disease course, but which is sensitive to therapeutic 
intervention. Subgroup analyses of the COIN trial on metastatic CRC suggested that patients with normal base-
line platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas 
those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemother-
apy and should not receive a treatment break30.
Regarding lymph node involvement, we failed to find a significant correlation with NLR, PLR and PC. This 
finding is not in line with previous studies, wherein Chiang et al. reported that patients with advanced pN stage 
also had significantly higher NLR values31. This difference cannot be easily explained, especially considering that 
the lymph node yield in our study was adequate, with a mean number of 21.4 harvested lymph nodes.
A potential explanation for the observed correlation between predictors of CRC and NLR, PLR or PC can be 
brought back to the putative immunological activities of cancer cells.
In particular, the correlation between H-NLR and the presence of systemic metastases can be explained by the 
fact that a high neutrophil count was found in our CRC patients, and these blood cells actively release cytokines 
and circulating vascular endothelial growth factor (VEGF), two molecules deeply involved in angiogenesis, can-
cer growth and metastasis32. On the other hand, lymphocytes play a pivotal role in tumour suppression, by induc-
ing cytotoxic cell death and cytokine production, which may ultimately contribute to inhibiting the proliferation 
and metastatic activity of cancer cells33, 34.
The biological background of the observed correlation between lymph node involvement and NLR, PLR or PC 
remains unexplained. Although Pine et al. previously found a correlation between high NLR and pN stage, this 
study also included non-curative resection and less than 15 lymph nodes were detected in half of the patients3.
Therefore, we tend to believe that the prognostic significance of these tests may be stronger for certain charac-
teristics of cancer progression such as depth invasion and systemic metastasis rather than for node involvement.
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When we considered Stage I-IV tumours, survival appeared to be worse in patients with H-NLR. This intrigu-
ing finding may be partly explained by the differences observed in cancer volume between the L-NLR and H-NLR 
groups, despite the fact that the prognostic significance of NLR for cancer-related survival could not be confirmed 
in multivariate analysis.
Unlike NLR and PLR, PC was significantly associated with 5-year overall and cancer-related survival after 
stratification of patients according to TNM stage. This is also reasonable since platelets may contribute to cancer 
development by promoting neoangiogenesis, increasing both microvessel permeability and extravasation of can-
cer cells, producing growth factors (e.g. VEGF, PDGF and TGF-β) and facilitating the interaction between cancer 
cells and endothelia at metastatic sites35, 36.
In conclusion, our study clearly demonstrates that the distribution of NLR, PLR and PC significantly dif-
fers between CRC patients and healthy subjects. This difference is more marked in advanced tumours, although 
it does not unequivocally reflect cancer-related survival. Further studies will be needed to establish the real 
cost-effectiveness of routinely using these inexpensive, readily available and reproducible biomarkers for estab-
lishing the prognosis after R0 resection for CRC.
Methods
Patients and eligibility criteria. The original patient population consisted of all patients undergoing sur-
gery for CRC at the Division of General Surgery A, University of Verona Hospital Trust, between January 2005 
and December 2013. Inclusion criteria were: elective surgery for histology-proven CRC and age of 18 years or 
older.
Patients with evidence of infections or other inflammatory conditions during preoperative evaluation were 
excluded, as well as those who underwent preoperative chemo or radiotherapy, emergency surgery and an R1 or 
R2 resection. All methods used in this study were performed in accordance with the relevant ethical guidelines 
and regulations of the University Hospital of Verona, where the investigation was carried out. Informed consent 
was obtained from all patients and the study protocol was approved by the local ethical committee (ID number: 
42763-CRINF-1034 CESC).
Preoperative work-up and histopathological staging. Prior to surgery, all patients were staged with 
colonoscopy, computed tomography (CT) of chest-abdomen and pelvis and measurement of cancer biomark-
ers including carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9). Additional imaging studies 
including magnetic resonance imaging (MRI) and endoluminal ultrasonography were used for staging rectal 
cancer. Liver MRI and positron emission tomography were also used to evaluate dubious lesions.
Pathology specimens were analysed in accord with the 7th Edition of the American Joint Committee on Cancer 
(AJCC) and the Union International Contre Le Cancer (UICC) criteria.
Preoperative assessment of laboratory data. Neutrophil count, lymphocyte count and PC were 
obtained in venous blood within 2 weeks from the date of surgery. NLR and PLR were calculated by dividing the 
absolute number of neutrophils or platelets by the absolute number of lymphocytes, respectively.
Blood samples were drawn by an expert phlebotomist in vacuum blood tubes containing K2-EDTA (Terumo 
Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens 
Healthcare Diagnostics, Tarrytown NY, USA). The local reference ranges are 150–400 × 109/L for platelets, 4.3–
10.0 × 109/L for total white blood cells (WBC), 2.0–7.0 × 109/L for neutrophils and 0.95–4.5 × 109/L for lympho-
cytes, respectively. The same analyser was used throughout the study period. The quality and comparability of 
test results was validated by data of both internal quality control (IQC) and external quality assessment (EQA).
Extent of surgery. The complete excision of the tumour burden (R0 resection) was the main outcome of 
surgery. The extent of surgery was planned according to patient conditions, tumour location and stage. Standard 
CRC resections (i.e. right hemicolectomy, extended right hemicolectomy, left hemicolectomy, anterior resection, 
low anterior resection, abdominoperineal resection) with ligation of vessels at their origin were usually performed 
in order to harvest an adequate number of lymph nodes37. The mean number of lymph nodes analyses was 21.4 
(SD, 11.4), with only 13.8% of cases having less than 12 lymph nodes excised. In patients affected by synchronous 
liver metastases or peritoneal disease, liver resection or partial peritonectomy was needed to achieve R0 resection.
Follow-up and statistical analysis. All clinical and pathological data were retrospectively collected and 
stored in a digital database. Demographic, clinical, surgical and pathology variables were analysed.
On preliminary analysis, preoperative NLR, PLR and PC were found to be normally distributed. The optimal 
cut-off values for NLR, PLR and PC as dichotomous predictors of survival was chosen after considering (i) con-
ventional receiver operating characteristics (ROC) curve analysis using death as the outcome (see Supplementary 
Fig. S1); (ii) Kaplan-Meier curves and proportional hazards regression with cut-off increased in following steps 
and results recalculated at each step in order to identifying the threshold associated with the greatest separation 
of curves with the lowest p value; (iii) evaluation of cut-offs proposed by previous literature. The distribution of 
NLR, PLR and PC in the final study population was also compared with the distribution of these parameters in 
a total number of 5270 healthy blood donors who had their blood collected during the same period (i.e. control 
group). The difference was analysed with ANOVA test (Table 1 and Fig. 1); the relationship between study vari-
ables (i.e. NLR, PLR and PC) and age was tested using linear regression analysis (see Supplementary Figs S4 and 
S5).
The significance of differences was evaluated with chi square test or Fisher’s exact test for categorical data 
(using NLR, PLR and PC as dichotomous variables), and Student’s t-test for continuous variables.
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The association of NLR, PLR and PC with overall survival and cancer-related survival was analysed using 
Kaplan-Meier curves and compared with the log-rank test. The time of survival was measured between the date 
of surgery and the date of the most recent follow-up examination or death. Multivariable analysis for overall 
survival and cancer-related survival was performed using Cox regression model by separately considering NLR, 
PLR and PC values above or below the relative cut-offs and adjusting for the following risk factors: age (>median 
vs. ≤median), gender (male vs. female), tumour location (rectum vs. colon), histological type (mucinous vs. 
non-mucinous type) and AJCC/UICC TNM stage (stage II, stage III and stage IV vs. stage I). A p value < 0.05 was 
considered to be statistically significant.
Statistical analysis was performed using SPSS software version 21.0 version (IBM Corporation, Armonk, NY) 
and STATA software (Stata Corporation, 2011, MP-Parallel Edition).
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